Celularity Inc
For the period ended Dec 31, 2023. Filed Jul 30, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Jul 30, 2024
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-in · Accumulated · Accumulated Other Comprehensive · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Income (Loss) | Equity | |
| Balances at December 31, 2021 | 12,430,788 | $12 | $763,087 | $(663,681) | $— | $99,418 |
| Cumulative effect adjustment ASU 2016-02 | — | — | 3,993 | — | 3,993 | |
| Reclassification of previously exercised stock options | 13,125 | — | 441 | — | — | 441 |
| Exercise of stock options | 171,047 | — | 948 | — | — | 948 |
| Purchase and retirement of common shares | (1,050) | — | (86) | — | — | (86) |
| Exercise of warrants | 1,328,189 | 2 | 46,489 | — | — | 46,491 |
| Common stock issued pursuant to short-term debt conversion | 262,797 | 1 | 4,098 | — | (11) | 4,088 |
| Vesting of restricted stock units | 23,252 | — | — | — | — | 0 |
| Tax withholding on vesting of restricted stock units | (7,067) | — | (132) | — | — | (132) |
| Stock-based compensation expense | — | — | 15,856 | — | — | 15,856 |
| Issuance of common stock to PIPE investor, net of issuance costs | 405,406 | — | 7,651 | — | — | 7,651 |
| Issuance of common stock in ATM offering, net of commissions and offering expenses | 265,641 | — | 6,021 | — | — | 6,021 |
| Change in fair value of debt due to change in credit risk, net of tax | — | — | — | — | 20 | 20 |
| Net income | — | — | — | 14,192 | — | 14,192 |
| Balances at December 31, 2022 | 14,892,129 | $15 | $844,373 | $(645,496) | $9 | $198,901 |
| Issuance of common stock in Registered Direct Offering, net of offering expenses | 1,780,220 | 2 | 1,320 | — | — | 1,322 |
| Common stock issued pursuant to short-term debt maturity extension | 270,731 | — | 712 | — | — | 712 |
| Exercise of stock options | 108,637 | — | 304 | — | — | 304 |
| Fair value of warrant modification for professional services | - | — | 403 | — | — | 403 |
| Issuance of common stock for stem-cells to be used in research and development | 169,492 | — | 1,000 | — | — | 1,000 |
| Issuance of warrants on senior secured bridge loans | - | — | 2,016 | — | — | 2,016 |
| Common stock issued pursuant to short-term debt conversion | 559,481 | 1 | 4,598 | — | (155) | 4,444 |
| Vesting of restricted stock units | 83,759 | — | — | — | — | 0 |
| Tax withholding on vesting of restricted stock units | (19,130) | — | (101) | — | — | (101) |
| Stock-based compensation expense | — | — | 15,017 | — | — | 15,017 |
| Issuance of common stock in PIPE Offering, net of offering expenses | 1,519,579 | 1 | 12,680 | — | — | 12,681 |
| Issuance of common stock under ATM Agreement | 13,296 | — | 136 | — | — | 136 |
| Change in fair value of debt due to change in credit risk, net of tax | — | — | - | — | 146 | 146 |
| Issuance of warrants to C.V. Starr | — | — | 274 | — | — | 274 |
| Net loss | — | — | - | (196,295) | — | (196,295) |
| Balances at December 31, 2023 | 19,378,192 | $19 | $882,732 | $(841,791) | $— | $40,960 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.